Related Experiment Videos
Infrequent ras oncogene point mutations in renal cell carcinoma
D M Nanus1, I R Mentle, R J Motzer
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021.
The Journal of Urology
|January 1, 1990
Summary
Ras oncogenes do not appear to play a significant role in renal cell carcinoma development. Researchers found mutated ras genes in only 2% of analyzed kidney cancers, suggesting they are not a major factor in cancer initiation or spread.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The role of ras oncogenes in renal cell carcinoma (RCC) pathogenesis is not well understood.
- Previous studies indicated that mutated ras oncogenes could initiate transformation events in kidney cells, suggesting a potential role in RCC.
Purpose of the Study:
- To investigate the involvement of ras genes in renal carcinogenesis.
- To determine the incidence of point mutations in Ha-ras, Ki-ras, and N-ras proto-oncogenes in primary and metastatic renal carcinomas.
Main Methods:
- Analysis of 51 primary and metastatic renal carcinomas, including oncocytomas.
- Detection of point mutations in codons 12, 13, and 61 of Ha-ras, Ki-ras, and N-ras genes.
- Utilized polymerase-catalyzed chain reaction (PCR) methodology.
Main Results:
- A mutated Ha-ras gene was identified in only one case (2%) of metastatic renal cancer.
- No mutations were found in the analyzed codons of Ki-ras or N-ras proto-oncogenes.
- The overall incidence of activated ras oncogenes in RCC was found to be very low.
Conclusions:
- Activated ras oncogenes, through point mutations, do not appear to be a major factor in the initiation, maintenance, or metastasis of renal cell carcinomas.
- The findings suggest that other molecular mechanisms are primarily responsible for the development of most renal cancers.
- Further research is warranted to explore alternative oncogenic pathways in RCC.